Pharmaceutical News and Articles

Nightmares Might Be Slowly Scaring Some To Death

MONDAY, June 23, 2025 Scared to death might not be just a saying, as far as nightmares are concerned. People who have frequent nightmares appear to have a tripl

Blood Test Might Predict Rapid Decline in Alzheimer's Patients

MONDAY, June 23, 2025 A common blood test can flag early Alzheimer s disease patients who are four times more likely to experience rapid brain decline, a new st

Weed Use Linked To Heart-Related Deaths

MONDAY, June 23, 2025 Weed is associated with a doubled risk of death from heart disease, a new evidence review shows. The study also found that marijuana use i

Genetic Tests For Autism, Intellectual Disability Not Being Done On Medicaid Kids

MONDAY, June 23, 2025 Few poor children with autism or intellectual disability are receiving recommended genetic testing, even though guidelines urge such tests

Menstrual Cycle Might Play A Role In Drinking

MONDAY, June 23, 2025 A woman s craving for alcohol might depend partially on her menstrual cycle, a pilot study says. Specifically, women appear to have higher

Lilly to Offer All Approved Doses of Zepbound (tirzepatide) Single-Dose Vials Through LillyDirect Self Pay Pharmacy Solutions

Eli Lilly and Company (NYSE LLY) today announced that the highest approved doses of Zepbound (tirzepatide) 12.5 mg and 15 mg will soon be available in single-do

Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity With a Third Achieving 25% or More

Bagsv rd, Denmark, 21 June 2025 Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American

Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (ustekinumab-stba), Expanding Dosing Options for Pediatric Patients

FDA Approves Once-Monthly Andembry for Hereditary Angioedema

The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attac

FDA Approves Twice-Yearly Yeztugo for Preexposure Prophylaxis to Cut HIV Risk

offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic, Carlos del Rio, M.D., from Em